Exclusive Summary

• First-in-class pan-mutation mechanism: As a first-in-class inhaled full-length CFTR mRNA therapy, it breaks the limitations of existing small molecule drugs that target limited specific mutations (e.g., Del508) to effectively cover all genetic mutation types in Cystic Fibrosis (CF) patients.
• Patented unique non-LNP delivery platform: Utilizing the world's first lyophilized non-LNP inhalation formulation, it successfully avoids the predominant pulmonary toxicity constraints posed by traditional LNP systems, boasts simpler CMC processes, and is already protected by submitted IP applications.
• Superior safety and excellent compliance: The portable nebulizer device delivering a weekly (QW) or bi-weekly (Q2W) dosage dramatically improves patient adherence over daily regimens, while current IIT clinical data unequivocally exhibits favorable safety with zero detected liver-related adverse events.
• Prime target for global MNC out-licensing: Targeting the multi-billion-dollar CF rare disease market predominantly localized in the US and Europe, the pipeline aligns perfectly with the unmet needs of global pharmas and is intrinsically equipped to qualify for FDA/EMA Orphan Drug Designations and expedited review pathways.

Asset Materials

Contact Us for Full Materials